RV01 is primarily used in research settings as a selective inhibitor of the NLRP3 inflammasome, a key component in the innate immune system involved in the production of pro-inflammatory cytokines. Its main application lies in studying inflammatory pathways associated with diseases such as Alzheimer's, type 2 diabetes, and atherosclerosis. By blocking NLRP3 activation, RV01 helps reduce the release of interleukin-1β (IL-1β) and interleukin-18 (IL-18), making it a valuable tool for investigating potential therapeutic strategies for chronic inflammatory and autoimmune conditions. It is also used in cellular and animal models to validate the role of NLRP3 in disease progression and to assess the efficacy of inflammasome-targeted treatments.